Calibrium is focused on new approaches to treat diabetes and related metabolic disorders. The Calibrium leadership team (including co-founders Richard DiMarchi and Fritz French) was previously affiliated with Marcadia Biotech, which was also focused on novel diabetes therapeutics and sold to Roche in 2010.